Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 2%

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) dropped 2% on Wednesday . The company traded as low as $16.21 and last traded at $16.37. Approximately 2,632 shares changed hands during trading, a decline of 98% from the average daily volume of 145,034 shares. The stock had previously closed at $16.70.

Wall Street Analyst Weigh In

TYRA has been the topic of a number of research analyst reports. Wedbush reiterated an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $23.00 price target on shares of Tyra Biosciences in a report on Wednesday. Finally, Oppenheimer reiterated an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a report on Wednesday.

Tyra Biosciences Trading Up 1.6 %

The business has a 50-day moving average of $17.67 and a 200-day moving average of $16.58.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.11. Equities analysts forecast that Tyra Biosciences, Inc. will post -1.71 EPS for the current year.

Insider Activity at Tyra Biosciences

In related news, COO Daniel Bensen sold 3,502 shares of Tyra Biosciences stock in a transaction on Monday, June 10th. The stock was sold at an average price of $20.00, for a total transaction of $70,040.00. Following the completion of the sale, the chief operating officer now owns 427,981 shares of the company’s stock, valued at $8,559,620. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 15.40% of the company’s stock.

Institutional Trading of Tyra Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Federated Hermes Inc. lifted its position in shares of Tyra Biosciences by 1,244.2% in the fourth quarter. Federated Hermes Inc. now owns 2,070 shares of the company’s stock worth $29,000 after buying an additional 1,916 shares during the last quarter. AJOVista LLC acquired a new stake in shares of Tyra Biosciences in the fourth quarter worth about $59,000. Exchange Traded Concepts LLC lifted its position in shares of Tyra Biosciences by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 9,531 shares of the company’s stock worth $132,000 after buying an additional 2,417 shares during the last quarter. Fishman Jay A Ltd. MI acquired a new stake in shares of Tyra Biosciences in the first quarter worth about $246,000. Finally, Victory Capital Management Inc. lifted its position in shares of Tyra Biosciences by 53.4% in the fourth quarter. Victory Capital Management Inc. now owns 50,220 shares of the company’s stock worth $696,000 after buying an additional 17,490 shares during the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.